Medicine details

ImageCavazide 75/12.5
NameCavazide 75/12.5
DosageTablet
Generic NameHydrochlorothiazide + Irbesartan
Classes Cardiovascular Agent
Antihypertensive
Antihypertensive Combination
Diseases Cardiovascular Disease
Hypertension (High Blood Pressure)
CompanyUnimed & Unihealth Manufacturers Ltd.

Drug Package Details

Strength12.5 mg + 75 mg
Storage Condition
Origin CountryBangladesh
Commercial Pack30
Price per pack180.00
Cost per pack158.40
Package unit10 tabs strip
Price per unit6.00
Cost per unit5.28
Discount0
Coupon
Remarks

Hydrochlorothiazide + Irbesartan

Hydrochlorothiazide + Irbesartan is a combination of Irbesartan an orally active, AT1 receptor subtype specific angiotensin II receptor blocker (ARB), and hydrochlorothiazide, a diuretic.

Hydrochlorothiazide + Irbesartan is indicated for the treatment of-

  • Hypertension

This fixed-dose combination is for adult patients whose blood pressure cannot be controlled satisfactorily with irbesartan or hydrochlorothiazide alone.

  • Patients who cannot manage their blood pressure with hydrochlorothiazide or irbesartan 150 mg alone may be given Hydrochlorothiazide + Irbesartan 150 mg/12.5 mg.
  • In patients who are not adequately controlled by irbesartan 300 mg or Hydrochlorothiazide + Irbesartan 150 mg/12.5 mg, Hydrochlorothiazide + Irbesartan 300 mg/12.5 mg may be used.
  • In patients who are not well controlled by Hydrochlorothiazide + Irbesartan 300 mg/12.5 mg, Hydrochlorothiazide + Irbesartan 300 mg/25 mg may be used.
  • It is not recommended to take more than 300 mg irbesartan/25 mg hydrochlorothiazide once a day.

Renal dysfunction:

Hydrochlorothiazide + Irbesartan is not indicated for people with severe renal impairment (creatinine clearance <30 ml/min) due to the hydrochlorothiazide component. In this demographic, loop diuretics are favored to thiazides. Patients with renal impairment who have a renal creatinine clearance of greater than 30 ml/min do not need to change their dosage.

Hepatic dysfunction:

In individuals with significant hepatic impairment, Hydrochlorothiazide + Irbesartan is not recommended. In patients with poor hepatic function, thiazides should be taken with caution. In individuals with mild to severe hepatic impairment, there is no need to change the dosage of Hydrochlorothiazide + Irbesartan.

Side effects commonly associated with the use of Hydrochlorothiazide + Irbesartan are-

  • Increases in blood urea nitrogen 
  • Dizziness
  • Nausea
  • Abnormal urination
  • Asthenia (fatigue)
  • Muscle pain (myalgia)
  • Influenza

 

  • During the second and third trimesters of pregnancy, medications that act on the renin-angiotensin system impair fetal renal function and increase fetal and newborn morbidity and death.
  • Symptomatic hypotension can occur in patients with an active renin-angiotensin system, such as volume- and/or salt-depleted patients on high doses of diuretics.
  • Patients whose renal function may depend in part on the activity of the renin-angiotensin system (e.g., patients with renal artery stenosis, chronic kidney disease, severe congestive heart failure, or volume depletion) may be at particular risk of developing acute renal failure on Hydrochlorothiazide + Irbesartan.

Contraindication

  •  Contraindicated to the patients who are sensitive to hydrochlorothiazide or to other sulfonamide-derived drugs, such as-
  • Contraindicated to the patients who are hypersensitive to irbesartan or other ARBs, such as-
  • Concomitant use of Hydrochlorothiazide + irbesartan with aliskiren containing products in patients with diabetes mellitus or renal impairment.
  • Hydrochlorothiazide + irbesartan potassium is contraindicated in pregnancy.
  • Hydrochlorothiazide + irbesartan potassium is contraindicated in patients with severe kidney problems (GFR 30 mL/min) and anuria due to the hydrochlorothiazide component.
  • Hydrochlorothiazide + irbesartan potassium is contraindicated in patients with significant hepatic problems or biliary cirrhosis and cholestasis due to the Telmisartan component.